- Home
- AMC vs EWTX Comparison
AMC vs EWTX Comparison
Compare AMC & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMC
- EWTX
- Stock Information
- Founded
- AMC 1920
- EWTX 2017
- Country
- AMC United States
- EWTX United States
- Employees
- AMC N/A
- EWTX N/A
- Industry
- AMC Movies/Entertainment
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- AMC Consumer Discretionary
- EWTX Health Care
- Exchange
- AMC Nasdaq
- EWTX Nasdaq
- Market Cap
- AMC 1.3B
- EWTX 1.5B
- IPO Year
- AMC 2013
- EWTX 2021
- Fundamental
- Price
- AMC $2.83
- EWTX $14.31
- Analyst Decision
- AMC Hold
- EWTX Buy
- Analyst Count
- AMC 7
- EWTX 9
- Target Price
- AMC $3.94
- EWTX $39.89
- AVG Volume (30 Days)
- AMC 8.6M
- EWTX 806.2K
- Earning Date
- AMC 11-05-2025
- EWTX 11-06-2025
- Dividend Yield
- AMC N/A
- EWTX N/A
- EPS Growth
- AMC N/A
- EWTX N/A
- EPS
- AMC N/A
- EWTX N/A
- Revenue
- AMC $4,915,600,000.00
- EWTX N/A
- Revenue This Year
- AMC $7.93
- EWTX N/A
- Revenue Next Year
- AMC $6.63
- EWTX N/A
- P/E Ratio
- AMC N/A
- EWTX N/A
- Revenue Growth
- AMC 9.42
- EWTX N/A
- 52 Week Low
- AMC $2.45
- EWTX $10.60
- 52 Week High
- AMC $5.56
- EWTX $38.12
- Technical
- Relative Strength Index (RSI)
- AMC 46.72
- EWTX 50.11
- Support Level
- AMC $2.75
- EWTX $13.85
- Resistance Level
- AMC $2.97
- EWTX $14.43
- Average True Range (ATR)
- AMC 0.08
- EWTX 0.64
- MACD
- AMC 0.02
- EWTX -0.10
- Stochastic Oscillator
- AMC 62.00
- EWTX 29.69
About AMC AMC Entertainment Holdings Inc.
AMC Entertainment Holdings Inc is involved in the theatrical exhibition business. It owns, operates, or has interests in theatres located in the United States and Europe. It provides amenities such as plush, power recliners, MacGuffins full bars, AMC Dine-In Theatres, and premium presentation. The company has identified two reportable segments and reporting units for its theatrical exhibition operations, U.S. markets and International markets. It derives key revenue from the U.S.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.